New therapies for type 2 diabetes mellitus

Manuel Puig-Domingo; Silvia Pellitero

doi:10.1016/j.medcli.2014.03.018

New therapies for type 2 diabetes mellitus

Manuel Puig-Domingo, Silvia Pellitero

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

4 Citations (Scopus)

Abstract

© 2014 Elsevier España, S.L.U. The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) has led to a growing interest in the investigation of new therapies. Treatment of T2DM has focused on the insulinopenia and insulin resistance. However, in the last 10 years, new lines of research have emerged for the treatment of T2DM and preclinical studies appear promising. The possibility of using these drugs in combination with other currently available drugs will enhance the antidiabetic effect and promote weight loss with fewer side effects. The data provided by post-marketing monitoring will help us to better understand their safety profile and potential long-term effects on target organs, especially the cardiovascular risk.

Original language	English
Pages (from-to)	560-565
Journal	Medicina Clinica
Volume	144
Issue number	12
DOIs	https://doi.org/10.1016/j.medcli.2014.03.018
Publication status	Published - 22 Jun 2015

Keywords

Future
Treatment
Type 2 diabetes mellitus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.medcli.2014.03.018

Cite this

@article{7263816cf8184e08a24f2a93684cdc17,

title = "New therapies for type 2 diabetes mellitus",

abstract = "{\textcopyright} 2014 Elsevier Espa{\~n}a, S.L.U. The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) has led to a growing interest in the investigation of new therapies. Treatment of T2DM has focused on the insulinopenia and insulin resistance. However, in the last 10 years, new lines of research have emerged for the treatment of T2DM and preclinical studies appear promising. The possibility of using these drugs in combination with other currently available drugs will enhance the antidiabetic effect and promote weight loss with fewer side effects. The data provided by post-marketing monitoring will help us to better understand their safety profile and potential long-term effects on target organs, especially the cardiovascular risk.",

keywords = "Future, Treatment, Type 2 diabetes mellitus",

author = "Manuel Puig-Domingo and Silvia Pellitero",

year = "2015",

month = jun,

day = "22",

doi = "10.1016/j.medcli.2014.03.018",

language = "English",

volume = "144",

pages = "560--565",

journal = "Medicina Clinica",

issn = "0025-7753",

number = "12",

}

TY - JOUR

T1 - New therapies for type 2 diabetes mellitus

AU - Puig-Domingo, Manuel

AU - Pellitero, Silvia

PY - 2015/6/22

Y1 - 2015/6/22

N2 - © 2014 Elsevier España, S.L.U. The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) has led to a growing interest in the investigation of new therapies. Treatment of T2DM has focused on the insulinopenia and insulin resistance. However, in the last 10 years, new lines of research have emerged for the treatment of T2DM and preclinical studies appear promising. The possibility of using these drugs in combination with other currently available drugs will enhance the antidiabetic effect and promote weight loss with fewer side effects. The data provided by post-marketing monitoring will help us to better understand their safety profile and potential long-term effects on target organs, especially the cardiovascular risk.

AB - © 2014 Elsevier España, S.L.U. The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) has led to a growing interest in the investigation of new therapies. Treatment of T2DM has focused on the insulinopenia and insulin resistance. However, in the last 10 years, new lines of research have emerged for the treatment of T2DM and preclinical studies appear promising. The possibility of using these drugs in combination with other currently available drugs will enhance the antidiabetic effect and promote weight loss with fewer side effects. The data provided by post-marketing monitoring will help us to better understand their safety profile and potential long-term effects on target organs, especially the cardiovascular risk.

KW - Future

KW - Treatment

KW - Type 2 diabetes mellitus

U2 - 10.1016/j.medcli.2014.03.018

DO - 10.1016/j.medcli.2014.03.018

M3 - Review article

SN - 0025-7753

VL - 144

SP - 560

EP - 565

JO - Medicina Clinica

JF - Medicina Clinica

IS - 12

ER -

New therapies for type 2 diabetes mellitus

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this